NASDAQ NMS - GLOBAL MARKET · IRWD
-1.16% · -$0.0500 · Vol Not reported
Pre-market · updated 05:02:32 ET
Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Biotechnology
$4.27
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
IRWD
Ironwood Pharmaceuticals Inc
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

81/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IRWD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IRWD catalysts
About Ironwood Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2010
Employees
100
Country
US

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.32
Last session
Day high
$4.32
Last session
Day low
$4.32
Last session
Previous close
$4.32
52W high
$5.39
-20.78% from high
52W low
$0.8363
75% of range
Market cap
$713.8M
P/E
4.64×
EPS
$0.9200
Beta
1.65
Shares out
165.2M
Avg volume
2.6M
VWAP
$4.32
Last session
Price history computed in-house
1W
-3.39%
1M
-4.47%
3M
+4.40%
1Y
+376.08%
YTD
+26.71%
SMA 50 $3.89 · above
SMA 200 $3.72 · above
52W position 75%

IRWD overview

Veridion Score
81
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IRWD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IRWD Form 4 filings
Public disclosures

Congress activity in IRWD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for IRWD in the cached public ledger.

Federal contracts

IRWD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IRWD in this window.
Lobbying spend

IRWD lobbying filings, year to date.

Registered lobbying filings matched to Ironwood Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IRWD in this window.
Loading news for IRWD
Analyst ratings
Sovereign unlock shows live analyst consensus for IRWD.
Options
Sovereign unlock shows live options positioning for IRWD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.